Ligand Pharmaceuticals Incorporated (LGND) 14.70 0.23

Ligand Pharmaceuticals, Inc.
(LGND) 14.70 0.23

Last Trade:	14.70	Day Range:	14.195 - 15.43
Trade Time:	08:02PM	52wk Range:	9.00 - 16.24
Prev. Close:	14.47	Market Cap:	289.2M
Open:	14.65	Div Yield:	0
Volume:	360539	PE:
EPS:	0.35

The Latest On LGND

MLV & Co Affirms Ligand Pharmaceuticals Buy, $30 PT 2/8/12 4:18pm

From Earlier: Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled, Propylene Glycol-Free Melphalan 2/2/12 7:24am

Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed 12/21/11 8:03am

Ligand Announces Positive Preclinical Data 12/12/11 4:30pm

Griffin Securities Initiates Ligand Pharma at Buy, $18 PT 11/22/11 10:31am

Edison Investment Research Expects Growth for Ligand Pharmaceuticals 11/14/11 8:31am

McNicoll, Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals 11/11/11 9:22am

Ligand Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting 11/7/11 9:02am

McNicoll Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals 11/7/11 8:06am

Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals? 11/2/11 7:46am

Ligand Announces Successful Phase II Results for Captisol-Enabled Propylene Glycol-Free Melphalan 11/2/11 7:07am

Ligand Enters into Platform Captisol License Agreement with SAGE Therapeutics 10/19/11 7:02am

MLV & Co Affirms Ligand Pharmaceuticals Buy, $30 PT 2/8/12

From Earlier: Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled, Propylene Glycol-Free Melphalan 2/2/12

Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed 12/21/11

Ligand Announces Positive Preclinical Data 12/12/11

Griffin Securities Initiates Ligand Pharma at Buy, $18 PT 11/22/11

Edison Investment Research Expects Growth for Ligand Pharmaceuticals 11/14/11

McNicoll, Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals 11/11/11

Ligand Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting 11/7/11

McNicoll Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals 11/7/11

Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals? 11/2/11

Ligand Announces Successful Phase II Results for Captisol-Enabled Propylene Glycol-Free Melphalan 11/2/11

Ligand Enters into Platform Captisol License Agreement with SAGE Therapeutics 10/19/11

Wednesday's Biotech Stocks Trading 9/8/11

Mad Money Lightning Round: Cramer Likes Ligand Pharmaceuticals 9/8/11

8 Stocks With Significant Insider Buying 6/10/11

Benzinga’s Top Pre- Market Gainers (TRBN, LGND, DYAX, VRGY, HIBB, NLST) 11/20/09

MLV & Co Affirms Ligand Pharmaceuticals Buy, $30 PT 2/8/12

Griffin Securities Initiates Ligand Pharma at Buy, $18 PT 11/22/11

Edison Investment Research Expects Growth for Ligand Pharmaceuticals 11/14/11

McNicoll, Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals 11/11/11

McNicoll Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals 11/7/11

McNicoll, Lewis & Vlak Reiterates Ligand Pharmaceuticals Buy, $30 Price Target 10/10/11

C.K. Cooper Reiterates Ligand Pharmaceuticals Buy, Raises PT 7/26/11

Trade LGND
NOW!

Partner Headlines

Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q/A) 2/10/12

Insiders Trading DDMG, FCN, CCMO 11/23/11

8 Stocks Rising on Unusual Volume 11/9/11

The Medicines Co Launches Argatroban - Analyst Blog 9/15/11

'Mad Money Lightning Round': Ligand Pharma Looks Good 9/7/11

5 Stocks Flashing Insider-Buying Alerts 8/31/11

Insiders Trading MLI, ACGL, LGND 8/31/11

Insiders Trading PAA, OPEN, VHI 8/22/11

First Profit - Screen of the Week 5/10/11

8 Stocks With Substantial Insider Buying 3/8/11

Press Releases

Ligand to Present at the BIO CEO and Investor Conference on February 13 2/9/12 Business Wire Story

Ligand Reports Fourth Quarter and Full Year 2011 Financial Results 2/7/12 Business Wire Story

Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development 2/7/12 Business Wire Story

Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings 2/1/12 Business Wire Story

Ligand to Report Fourth Quarter Results on February 7 2/1/12 Business Wire Story

La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist 1/20/12 Business Wire Story

Ligand to Present at the Biotech Showcase Conference on January 10th 1/4/12 Business Wire Story

Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly 12/21/11 Business Wire Story

Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology 12/12/11 Business Wire Story

Ligand to Present at the Oppenheimer Healthcare Conference on December 14 12/7/11 Business Wire Story

Ligand Pharmaceuticals Announces Third Quarter Results 11/8/11 Business Wire Story

Ligand Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting 11/7/11 Business Wire Story

Get the latest LGND stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Ligand Pharmaceuticals, Inc. stock price.

Ligand Pharmaceuticals, Inc. by YCharts